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The response rate to combination chemotherapy (CT) of advanced
soft tissue sarcoma (STS) is 27–45%, with complete response
(CR) rate around 10% (Schutte et al, 1990; Steward et al, 1993;
Santoro et al, 1995; Saeter et al, 1997). Of all patients treated with
CT, 15% were longtime survivors and 5–6% could possibly be
cured (Benjamin, 1998; Wiklund et al, 1997).
In order to gain prolonged survival in a few individuals, many
must be exposed to the side-effects of CT. A test able to identify
those patients who are going to benefit from CT would therefore
be of great benefit. It is known that the performance status affects
CT response (Borden et al, 1990). However, little is known about
tumour-related factors which might predict CT response in STS. In
several other tumours a high proliferation rate has been shown to
be one of the factors increasing responsiveness to CT (Mattern et
al, 1986; Remvikos et al, 1989; O’Reilly et al, 1992; Hietanen et
al, 1995).
Several methods are available to measure the proliferation
activity of tumour cells. Determination of the tumour nuclear
antigen Ki-67 and S phase fraction (SPF) by flow cytometry are
two of the most studied ones (Gerdes et al, 1984; Hedley, 1989). In
recent years knowledge concerning the regulation of the cell cycle
has increased. Cyclins together with cyclin dependent kinases
(cdk) control the cell cycle by phosphorylation. Every cyclin has
its specific time of appearance in the cell cycle. Cyclin A is essen-
tial for the DNA replication in the S phase and it is active during
the initiation of mitosis. There are very few reports on cyclin A as
a marker of proliferative cell fraction in cancer. In two recent
studies by Volm, tumour tissue negativity for cyclin A expression
predicted a favourable outcome in non-small-cell lung cancer
patients (Volm et al, 1997, 1998). We are aware of no previous
studies correlating cyclin A score of the tumour to chemotherapy
response.
Studies on breast cancer have shown that patients whose
primary tumour has high proliferative activity respond better to
CT (Remvikos et al, 1989; O’Reilly et al, 1992; Hietanen et al,
1995). Similar results have been obtained in a melanoma study
(Karlsson et al, 1996). Only one study, as far as we know, has
investigated the prediction of CT response in STS patients
(Schmidt et al, 1993). In this study there was a tendency towards
better histopathologically verified CT response if the tumour had a
high SPF, although the result was not statistically significant.
The purpose of the present study was to find out whether
tumour cell proliferation could predict CT response and outcome
in STS patients. We collected the clinical data and evaluated the
CT responses in 75 STS patients treated in our institution by the
same combination CT regimen (IADIC). The proliferation rate of
the primary tumour samples was determined by flow cytometric
SPF and immunohistochemically by Ki-67 and cyclin A scores.
PATIENTS
Consecutive patients treated between June 1988 and January 1997
at the Department of Oncology, Helsinki University Central
Hospital, with the IVADIC regimen were included in the study.
Twenty-eight of these patients were included in a previously
published phase II CT study (Wiklund et al, 1992). The CT
schedule is shown in Table 1. Since October 1995 vincristine was
deleted from the schedule (IADIC).
Twenty cases were excluded from the study, eight due to
unavailable histological samples; the response rate in these cases
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Correspondence to: RL Huuhtanenwas 50% (4/8). Twelve cases were excluded since the CT response
was not evaluable. One patient had received radiotherapy to all
measurable lesions just prior to CT, one was given early radio-
therapy during the treatment, the lesions were not measurable in
two cases, two cases had poor performance status and did not
receive the scheduled treatment, in two cases the documentation of
the response was insufficient, and in four cases the patient
received only one CT cycle due to the patients’ refusal or compli-
cations.
The pretreatment characteristics of the 55 patients included in
the study are shown in Table 2. In 42 cases all three proliferation
measurements were available (SPF n = 50, Ki-67 score n = 47 and
cyclin A score n = 48).
The median time from diagnosis to beginning of CT was 335
days (range 6–4609 days). The number of patients still alive was
19, and seven of them were disease-free. The median follow-up
time of the living patients was 18 months (range 7–85 months).
Thirty-six patients died of their disease.
METHODS
The CT response evaluation was made retrospectively according
to Miller et al (1981). RH made the response evaluation by
reviewing patients’ documents and diagnostic images. CR and
partial responses (PR) were also evaluated by TW. Only patients
with stable disease for at least 3 months were classified into the 
no change (NC) group. Some patients were given radiotherapy,
underwent surgery or changed the CT schedule before objective
signs of progression were recorded. In these patients the follow-up
for progressive disease (PD) was cut off at the first day of surgery
or radiotherapy, or beginning of a new CT schedule.
Formalin-fixed, paraffin-embedded primary tumour samples
were collected. Sample deparaffination was done in xylene and
rehydration in alcohol to distilled water. Antigen demasking was
carried out by heating the samples in a microwave oven (850 W) in
citric acid buffer (pH 6, 0.1 M) for 20 min, buffer was added in
need. Treatment with 1.6% methanolperoxidase was used to
inhibit endogenous peroxidase activity. For immunohistochem-
istry, the specimens were incubated overnight at room temperature
with 1:100 diluted mouse monoclonal antibody to human cyclin A
(Novocastra), and for Ki-67 determination with 1:500 mouse anti-
human monoclonal Mib-1 antibody (PharMingen). The binding of
the primary antibody was detected by a peroxidase-conjugated
secondary antibody using the Vectastain® ABC kit (Vector
Laboratories Inc.). The sections were counterstained with haema-
toxylin. As positive and negative controls for cyclin A stainings,
we used hyperplastic tonsil tissue in cyclin A stainings. The
primary antibody was omitted from the negative controls.
We chose the tumour area with the highest density of positive
nuclear staining for quantification of the immunostaining. To
calculate the percentage of positively stained nuclei, an ocular grid
of 100 (10 ´ 10) squares was used at 10 ´ 40 magnification. All
positive nuclei from this area were counted. To estimate the nega-
tive nuclei in the same area of 100 squares, three different rows of
10 squares were counted and the mean score multiplied by 10. In
the case of tumours of scarce cellularity, several fields were evalu-
ated, and negative nuclei were counted from the whole grid area of
a hundred squares. The percentage of positive nuclei was counted
by dividing the number of the positive stained cells by the entire
number of cells in the same area. All samples were scored by two
independent observers (RH and TB). In the case of more than 5%
interobserver difference in the result, the sample was rescored by
the two investigators together.
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Table 1 IADIC treatment schedule
Agent Dose Schedule
Ifosfamide 1 g/m2/day i.v. days 1–5
Vincristinea 1.5 mg/m2 i.v. day 1
Doxorubicin 50 mg/m2 i.v. day 1
Dacarbazine 250 mg/m2/day i.v. days 1–5
Mesna 0.2 g/m2´3/day i.v. days 1–5
i.v. = intravenously. aVincristine was deleted from the schedule in October
1995.
Table 2 Pretreatment characteristics of the patients and chemotherapy
response rates according to the pretreatment characteristics
n (%) Response rate %
Sex
Female 33 (60) 52
Male 22 (40) 36
WHO performance status
0 27 (49) 52
1 26 (47) 38
2 2 (4) 0
Age
Median (range), years 50 (16–70)
Primary location
Visceral 21 (38) 48
Limb 22 (40) 55
Trunk 6 (11) 17
Head and neck 3 (5.5) 67
Unknown 3 (5.5) 0
Stage of disease
Metastatic disease 36 (66) 44
Primary tumour and metastasis 5 (9) 60
Local recurrence 4 (7) 75
Local recurrence and metastasis 10 (18) 30
Metastasis site
Pulmonary 29 (57) 48
Pulmonary and other 15 (29) 33
Other without pulmonary 7 (14) 71
Ploidy
Diploid 30 (59) 40
Non-diploid 21 (41) 43
Grade
Low (1–2) 9
High (3–4) 46
Histology
Malignant fibrous histiocytoma 11 56
Liposarcoma 4 50
Leiomyosarcomaa 13 62
Gastrointestinal stromal cell tumour 3 33
Synovial sarcoma 6 33
Extraskeletal Ewing’s sarcoma 2 100
Fibrosarcoma 2 0
Unclassified sarcoma 7 14
Other sarcomasb 42 5
Rhabdomyosarcoma 3 67
aSix uterine primaries. bCystosarcoma phylloides malignum, epithelioid
sarcoma, angiosarcoma, malignant schwannoma.In flow cytometric measurements, a modification of the basic
Hedley method was used (Hedley, 1989; Heiden et al, 1991). The
sections (100 mm) from the paraffin blocks were placed into fine-
mesh bags which were inserted into cassettes and then dewaxed and
rehydrated in a tissue processor. Enzymatic digestion was done
with Subtilisin Carlsberg (Sigma Protease type 24) and all centri-
fugation steps were omitted, resulting in nuclei suspensions with
extremely low amounts of clumped nuclei and debris. The nuclei
were stained with DAPI (final concentration 5 mmol) and analysed
using a PAS 2 flow cytometer. To confirm the ploidy of near diploid
populations, the DNA content of identified nuclei was measured by
means of a static image analysis system. Tumours were considered
diploid if only one G1-peak was present. For determination of the
DNA index in grossly aneuploid cell populations, the first peak to
the left was assumed to represent diploid cells. For the determina-
tion of the percentage of cells in the S phase of the cell cycle, the
MultiCycle program with the sliced-nuclei option for background
subtraction developed by Rabinowich was used (Phoenix Flow
System, San Diego, CA, USA).
Statistical methods
The Macintosh Statistica® program was used for most statistical
analyses. Correlations between ordinal variables were calculated
with Spearman rank order correlation test. Progression-free
survival (PFS) and overall survival (OS) analysis were calculated
with the Cox regression model. Proliferative indexes were used as
continuous variables. PFS and OS curves were calculated by the
Kaplan–Meier model by the Macintosh SPSS® program. PFS, OS
after CT and disease-free time after CR have been calculated from
the beginning of CT.
RESULTS
Eight patients (14%) had a CR, 17 (31%) PR, 18 (33%) had NC
and 12 (22%) PD. The response rates according to pretreatment
characteristics are shown in Table 1. The median disease-free time
in completely responding patients was 11 months (range 9–85
months).
The median cyclin A was 11.5% (range 1–52%). The median S
phase was 5.25% (range 0.4–30.9%). The median SPF of diploid
tumours was 4.5% (range 0.4–22.5%) and in non-diploid tumours
11.7% (range 2.8–30.9%). Median Ki-67 was 19% (range 2–45%).
Table 3 shows the number of patients in each response class
divided according to the median of cyclin A score, SPF and Ki-67
score. The medians and ranges of cyclin A score, SPF and Ki-67
score in each response class are shown in Table 4. Figure 1 shows
the median cyclin A scores, ranges and quartiles according to CT
response.
A significantly higher CT response rate was found in tumours
with high cyclin A score (P = 0.02), while no significant correla-
tion was found for SPF or Ki-67 score (P = 0.3 and P = 0.2 respec-
tively). SPF or Ki-67 score did not predict PFS (P = 0.75 and P =
0.2 respectively) or OS (P = 0.76 and P = 0.7 respectively). The
median PFS was 3.7 months when the primary tumour cyclin A
score was below the median, vs. 9.3 months when the cyclin A
score was above the median (P = 0.04) (Figure 2). The median OS
time from the beginning of CT was 13.4 months when the cyclin A
score was below the median, and 18 months when the cyclin A
score was above the median (P = 0.1) (Figure 3).
DISCUSSION
We have demonstrated that an immunohistochemically determined
high cyclin A score predicted a better CT response and a longer
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Figure 1 The median cyclin A scores, ranges and quartiles in different
chemotherapy response groups
Figure 2 Progression-free survival time. The thin line indicates patients
whose cyclin A score is above the median (11.5%) and the bold line shows
the cyclin A scores below or equal to the median
Figure 3 Overall survival time. The thin line indicates patients whose cyclin
A score is above the median (11.5%) and the bold line shows the cyclin A
scores below or equal to the medianPFS in patients with advanced STS. All the patients who reached
CR had a cyclin A score above the median.
Although the Ki-67 score and SPF did not predict CT response
or progression-free survival in this material, there was a tendency
for those patients who reached CR to have more often a Ki-67
score or SPF above the median than those who did not. Due to our
limited sample size, which diminished the statistical power, the
moderate predictive power of these two proliferation measure-
ments cannot be excluded. Because STS is a rare disease, the
possibility of collecting a larger sample size is limited.
The longer time to progression after CT is noteworthy since in
our previous study patients whose primary tumour had a high
cyclin A score had shorter OS and time to metastasis after primary
treatment than those patients whose primary tumour had a low
cyclin A score, and only six out of 126 (5%) patients received
adjuvant chemotherapy (Huuhtanen et al, 1999). This suggests a
prominent effect on the natural course of the disease by CT in
patients whose tumours have a fast proliferation rate. A similar
correlation between a high proliferation rate and improvement of
prognosis by CT has previously been noted in other malignancies
including breast cancer, melanoma and lymphoma. (Joensuu et al,
1994; Stål et al, 1994; Hahka-Kemppinen et al, 1997).
The CR group differs clearly from the other patients by the
significantly higher median values of cyclin A score, SPF and Ki-
67 score. The PR group did not show such difference. The study
by Wiklund et al (1997) suggested that the group of patients with
clinical PR is heterogenous. When surgical resection of metastasis
was performed after CT, clinical PR correlated poorly with the
histopathological CT response (Wiklund et al, 1997). In the
smaller study by Schmidt et al (1993), the correlation with clinical
and histopathological CT response in STS was similar in 70% of
the cases.
We have previously shown that cyclin A, Ki-67 score and SPF
correlate strongly to each other. However, cyclin A gave more
information about the prognosis compared to SPF and Ki-67 score
(Huuhtanen et al, 1999). The present investigation indicates that
cyclin A score predicted the clinical behaviour of the disease
better than the two other proliferation markers, also with respect to
the response to cytotoxic treatment. These different markers of
proliferation reflect the different phases of the cell cycle. As cyclin
A is active from the beginning of S phase to the beginning of
mitosis, it reveals the cell cycle phases most sensitive to CT drugs
(Mattern et al, 1986; McLaughlin, 1994). In the study by Volm,
breast cancer cell lines with high cyclin A were significantly more
sensitive to doxorubicin than cell lines with low cyclin A activity
(Volm et al, 1997). As far as we know, the present study is the first
one to demonstrate a significant tumour-related predictive factor
for STS, as well as being the first study of cyclin A and CT
response in any malignancy.
It has been debated whether patients with metastatic STS should
be treated at all by CT (Rouesse and Bourgeois, 1998). While a CR
of metastatic STS to CT in many cases is associated with a long
survival, perhaps even complete recovery in some patients, the
proportion of CR with the present drug combinations is disappoint-
ingly low (Wiklund et al, 1997; Benjamin, 1998). Thus any method
able to select patients with tumours which potentially are sensitive
to CT would be of great clinical value. Based on the present study,
proliferation determination by cyclin A score is a promising tool
for gaining more information in the selection of different STS treat-
ment options. Since a high cyclin A score is predictive for a
favourable chemotherapy response as well as for an increased risk
of relapse in primary disease it might also be useful for choosing
patients with STS benefiting from adjuvant chemotherapy; a more
extensive material would clarify the subject.
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